Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Larimar Therapeutics (LRMR) Amortization of Deferred Charges (2016 - 2017)

Larimar Therapeutics (LRMR) has disclosed Amortization of Deferred Charges for 4 consecutive years, with $3000.0 as the latest value for Q3 2017.

  • For the quarter ending Q3 2017, Amortization of Deferred Charges fell 66.67% year-over-year to $3000.0, compared with a TTM value of $13000.0 through Dec 2017, down 69.77%, and an annual FY2017 reading of $13000.0, down 69.77% over the prior year.
  • Amortization of Deferred Charges was $3000.0 for Q3 2017 at Larimar Therapeutics, roughly flat from $3000.0 in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $17000.0 in Q3 2014 and bottomed at $3000.0 in Q2 2017.
  • Average Amortization of Deferred Charges over 4 years is $11153.8, with a median of $11000.0 recorded in 2016.
  • The sharpest move saw Amortization of Deferred Charges surged 40.0% in 2015, then plummeted 72.73% in 2017.
  • Year by year, Amortization of Deferred Charges stood at $10000.0 in 2014, then soared by 40.0% to $14000.0 in 2015, then fell by 28.57% to $10000.0 in 2016, then tumbled by 70.0% to $3000.0 in 2017.
  • Business Quant data shows Amortization of Deferred Charges for LRMR at $3000.0 in Q3 2017, $3000.0 in Q2 2017, and $7000.0 in Q1 2017.